Mov Disord Vol 35, Suppl 1 Archives - Page 28 of 149 - MDS Abstracts

MDS Virtual Congress 2020
Spreading ɑ-synuclein pathology initiated from the sublaterodorsal tegmental nucleus models RBD followed by Parkinsonian phenotypes in mice
Y. Shen, W.B Yu, B. Shen, H. Dong, J. Zhao, Y. Fan, Y.F Yang, Y.M Sun, Y.L Tang, F.T Liu, JJ. Wu, B.G Xiao, H. Yu, J. Koprich, Z.L Huang, J. Wang (Shanghai, China)
Objective: To recapitulate ɑ-synucleinopathy based RBD-like behaviors in mice which could further proceed to develop Parkinsonian behavioral and histopathological phenotypes. Background: Idiopathic REM sleep behavior…
MDS Virtual Congress 2020
Profiling Atypical Anxiety in Parkinson’s Disease
E. Forbes, G. Byrne, J. O'Sullivan, J. Yang, N. Dissanayaka (St Lucia, Australia)
Objective: We aimed to identify the demographic, psychiatric, clinical and cognitive characteristics associated with Anxiety not otherwise specified (NOS) in persons with Parkinson’s disease (PWP).…
MDS Virtual Congress 2020
Impulse control disorder in the patients of Parkinson’s disease: Various correlations
M. Waghralkar, V. Gupta, A. Jukkarwala (Udaipur, India)
Objective: 1. To estimate the point prevalence of ICD in the local cases of PD using the series of rating scales. 2. To examine the…
MDS Virtual Congress 2020
A retrospective analysis of multicenter brain signal data recorded in Parkinson’s subjects implanted with deep brain stimulation leads
M. Case, H. Bronte-Stewart, A. Kuhn, K. Botzel, A. Hebb, P. Starr, B. Klassen, N. Ince, Z. Blumenfeld, J. Neumann, F. Hell, S. Hanrahan, N. Swann, M. Ozturk, S. Stanslaski, S. Goetz, T. Denison, K. Bhatia, R. Raike (Fridley, MN, USA)
Objective: To assess the prevalence and factors of detectable local field potential (LFP) signals in the subthalamic nucleus (STN) of Parkinson’s disease (PD) patients. Background:…
MDS Virtual Congress 2020
Varenicline for the Treatment of Postural and Gait Dysfunction in Parkinson’s Disease
D. Hall, S. Kapur, C. Vaughan, J. Hawkins, G. Stebbins (Chicago, IL, USA)
Objective: To determine if varenicline is effective for balance in Parkinson’s disease (PD). Background: Incidence of falls resulting from imbalance is estimated at 68% for…
MDS Virtual Congress 2020
Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients With Parkinson’s Disease: Impact on Dyskinesia
K. Klos, J. Hui, B. Robottom, P. Bhargava, B. Navia (Tulsa, OK, USA)
Objective: Assess impact of apomorphine sublingual film (APL-130277; APL) on time spent with and functional impact of dyskinesia among patients with Parkinson’s disease (PD) and…
MDS Virtual Congress 2020
Serious games home rehabilitation program to treat gait and balance disorders in patients with Parkinson’s disease: A randomised controlled trial
D. Nuic, S. de Weijer, E. Zeeboer, C. Olivier, S. Cherif, P. Foulon, B.R Bloem, N. De Vries, M.L Welter (Paris, France)
Objective: To test the efficacy of an exergame rehabilitation programme at home to treat dopa-resistant gait and balance disorders in Parkinson’s disease (PD) patients. Background:…
MDS Virtual Congress 2020
Directional versus Omnidirectional Deep Brain Stimulation: Results of a Multicenter Prospective Blinded Crossover Study
A. Schnitzler, P. Mir, M.A Brodsky, L. Verhagen, S. Groppa, R. Alvarez, A. Evans, M. Blazquez, S. Nagel, W. Libionka, J. Pilitsis, M. Pötter-Nerger, W. Tse, L. Almeida, N. Tomycz, J. Jimenez-Shahed, F. Carrillo, C.J Hartmann, S.J Groiss, F. Defresne, E. Karst, B. Cheeran, J. Vesper (Plano, TX, USA)
Objective: To compare the range of stimulation amplitudes that can relieve symptoms without side effects, between directional and omnidirectional DBS. Background: Published reports on directional…
MDS Virtual Congress 2020
Budget Impact of Apomorphine Sublingual Film for On-Demand Treatment of Patients With Parkinson’s Disease and “OFF” Episodes
A. Thach, N. Kirson, M. Zichlin, I. Dieye, E. Pappert, G. Williams (Marlborough, MA, USA)
Objective: To estimate the budget impact of introducing apomorphine sublingual film (APL-130277; APL) as an on-demand treatment for patients with Parkinson’s disease (PD) and “OFF”…
MDS Virtual Congress 2020
Super-Responders to Opicapone Adjunct Treatment to Levodopa in Parkinson’s Disease Patients with Motor Fluctuations: Combined Post-Hoc Analysis of BIPARK-I and II
A. Antonini, W. Poewe, J. Ferreira, G. Ebersbach, H. Gama, J.F Rocha, D. Magalhães, P. Soares-da-Silva (Padova, Italy)
Objective: To evaluate the efficacy and safety of opicapone (OPC) in Parkinson’s disease (PD) patients who were considered ‘super-responders’ (>= 2 hours of OFF-time reduction…